Kumar, Aneeta; Ferro Desideri, Lorenzo; Ting, Magdalene Yin Lin; Anguita, Rodrigo (2024). Perspectives on the currently available pharmacotherapy for wet macular degeneration. Expert opinion on pharmacotherapy, 25(6), pp. 755-767. Informa Healthcare 10.1080/14656566.2024.2354921
Full text not available from this repository.INTRODUCTION
Wet age-related macular degeneration (w-AMD) is a leading cause of visual impairment globally, with its prevalence expected to rise alongside increasing life expectancy. The current standard treatment involves frequent intravitreal injections of anti-VEGF agents, which although revolutionary, pose significant burdens on both patients and healthcare services.
AREAS COVERED
This review explores current and emerging pharmaceutical treatments for w-AMD, focusing on their pharmacokinetics, pharmacodynamics, efficacy, and safety. Promising developments include extending treatment intervals with newer anti-VEGF agents like brolucizumab and faricimab, biosimilars offering cost-effective options, and exploring innovative drug delivery methods such as subretinal gene therapy. Combination therapies, gene therapies, and novel agents like KSI-301 and OPT-302 show potential for improving treatment outcomes and reducing treatment burden.
EXPERT OPINION
While current treatments for w-AMD have significantly advanced with the advent of anti-VEGF therapies, their limitations in terms of treatment burden and incomplete responses have spurred research into diverse alternative approaches. These innovative strategies offer hope for improving patient outcomes and reducing healthcare burdens, suggesting a promising future for w-AMD management.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology |
UniBE Contributor: |
Ferro Desideri, Lorenzo, Anguita Henríquez, Rodrigo Andrés |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1465-6566 |
Publisher: |
Informa Healthcare |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
13 May 2024 15:35 |
Last Modified: |
08 Jun 2024 00:15 |
Publisher DOI: |
10.1080/14656566.2024.2354921 |
PubMed ID: |
38738427 |
Uncontrolled Keywords: |
Age-related macular degeneration Anti-VEFG KSI-301 OPT-302 novel treatment port delivery system |
URI: |
https://boris.unibe.ch/id/eprint/196732 |
Actions (login required)
 |
Edit item |